Clearmind Medicine achieves ‘positive’ results in cocaine addiction treatment

Clearmind Medicine announced achievement of “positive results” in addiction treatment for its revolutionary treatment targeting cocaine addiction.The company said, “This groundbreaking development is centered around the company’s innovative psychedelic molecule, MEAI, marking a significant milestone in the battle against addiction.” The trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University in Israel, was carried out following a previous experiment that showed a marked decrease in cocaine-induced craving among rats treated with MEAI. This research resulted in a patent application in the U.S., that is part of the company’s ongoing collaboration with SciSparc (SPRC). The collaboration focused on combining Clearmind’s MEAI, a novel proprietary psychedelic treatment for addiction, with SciSparc’s CannAmide. As part of this collaboration Clearmind filed a provisional patent application related to cocaine addiction.